engleski

Ruxolitinib treatment improves muscle mass in patients with myelofibrosis

We retrospectively investigated psoas muscle area (PMA)at vertebra L3 level from baseline and 6- month CT scans of myelofibrosis patients from two Croatian hematology centers that were treated with ruxolitinib due to high or intermediate-2 risk disease. Data for a total of 13 patients were available. PMA improvement of 10% was associated with higher baseline hemoglobin level (median 117 vs 95 g/L ; P = 0.034) and lower International Prognostic Scoring System (IPSS) score (2 vs 4 ; P = 0.019)Improvement in PMA was significantly correlated with decline in the longest spleen diameter (Rho = − 0.57 ; P = 0.042). Patients with less advanced disease were more likely to achieve better PMA improvement favoring early start of ruxolitinib therapy.

ruxolitinib, myelofibrosis

nije evidentirano